Unknown

Dataset Information

0

Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells.


ABSTRACT: KRAS is mutated in >90% of pancreatic ductal adenocarcinomas. As its inactivation leads to tumour regression, mutant KRAS is considered an attractive target for anticancer drugs. In this study we report a new delivery strategy for a G4-decoy oligonucleotide that sequesters MAZ, a transcription factor essential for KRAS transcription. It is based on the use of palmitoyl-oleyl-phosphatidylcholine (POPC) liposomes functionalized with lipid-modified G4-decoy oligonucleotides and a lipid-modified cell penetrating TAT peptide. The potency of the strategy in pancreatic cancer cells is demonstrated by cell cytometry, confocal microscopy, clonogenic and qRT-PCR assays.

PROVIDER: S-EPMC5144097 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC3627599 | BioStudies
| S-EPMC4677363 | BioStudies
| S-EPMC3169596 | BioStudies
| S-EPMC5778462 | BioStudies
| S-EPMC6284578 | BioStudies
| S-EPMC7504130 | BioStudies
| S-EPMC4737153 | BioStudies
| S-EPMC8675163 | BioStudies
| S-EPMC2903372 | BioStudies
| S-EPMC3303834 | BioStudies